Table 2.
Survival outcomes among SARS-CoV-2-positive vs. -negative patients.
| Outcome | No of Studies |
Events/Participants | Events | Heterogeneity between Trials |
p-Value for Differences across Groups |
|||
|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 (+) | SARS-CoV-2 (−) | OR | 95%CI | p-Value | I2 Statistic |
|||
| ROSC | 6 | 173/757 (22.9%) |
582/2058 (28.3%) |
0.69 | 0.52 to 0.92 | 0.23 | 27% | 0.01 |
| SHA | 4 | 51/582 (8.8%) |
277/1498 (18.5%) |
0.44 | 0.22 to 0.88 | 0.07 | 58% | 0.02 |
| SHD | 4 | 2/115 (1.7%) |
25/591 (4.2%) |
0.98 | 0.25 to 3.83 | 0.37 | 5% | 0.97 |
| SHD with CPC 1-2 | 2 | 2/18 (11.1%) |
7/186 (3.8%) |
2.67 | 0.47 to 15.28 | 0.58 | 0% | 0.27 |
| 30-day survival | 3 | 4/606 (0.7%) |
299/7055 (4.2%) |
0.12 | 0.05 to 0.31 | 0.63 | 0% | <0.001 |
Legend: CI = confidence interval; CPC = Cerebral Performance Categories Scale; OR = odds ratio; ROSC = return of spontaneous circulation; SHA = survival to hospital admission; SHD = survival to hospital discharge. Note: Not all outcomes were reported in every study. “No. of studies” refers to the studies included in the analysis for the particular outcome.